106Postersferentation by BM stromal cells inhibiting theosteoblast marker osteocalcin and collagen I. In conclusio<strong>no</strong>ur date indicate that human myeloma cellsinhibit osteoblast proliferation, induce osteoblastapoptosis and decrease human osteoblastogenesis.These effects could be responsible of the decreasedbone formation observed in MM patients.PO-071EXPRESSION OF OSTOPONTIN BY HUMAN MYELOMA CELLSAND ITS INVOLVEMENT IN MYELOMA INDUCED ANGIOGENESISColla S,* Morandi F,* Mancini C,° Lazzaretti M,°Crug<strong>no</strong>la M,* Rizzoli V,* Giuliani N**Cattedra di Ematologia and °Anatomia patologica,Università di Parma, ItalyOsteopontin (OPN) is a multifunctional bone matrixglycoprotein that interacts with CD44 as major receptor.OPN has been shown to be involved in angiogenesis,cell survival and tumor progression. In this studywe have investigated the production and the potentialrole of OPN in multiple myeloma (MM). First, we foundthat human myeloma cells expressed OPN mRNA andits regulating gene the core-binding factor (CBFA1).OPN protein production and release by myeloma cellshave been also demonstrated by westernblot analysisand ELISA assay, respectively. Moreover we found thatIL-6 and IGF-I induced an increase of OPN productionby myeloma cells and in turn OPN stimulated myelomacell proliferation. In an in vitro angiogenesis systemwe show that OPN production by myeloma cellscontribute to the pro-angiogenetic effect of myelomacells. OPN production was investigated in 52 newlydiag<strong>no</strong>sed MM patients stage I-III. In this cohort ofpatients we found that purified bone marrow (BM)CD138 + MM cells from 20 out of 52 patients expressedOPN. Higher OPN protein levels were detected in BMplasma of MM patients in comparison to control subjects,moreover BM angiogenesis was significant higherin MM patients positive for OPN as compared tothose negative. In conclusion our data highlight thatOPN is directly produced by human myeloma cells anddetected in a subset of MM patients with higherangiogenesis suggesting a potential involvement ofOPN in the pathophysiology of MM.PO-072VASCULOGENESIS IN PATIENTS WITH MULTIPLE MYELOMATHROUGH BONE MARROW MACROPHAGESRusso F, Ria R, Roccaro AM, Scavelli C, Cirulli T,Di Pietro G, Vacca A, Dammacco FDepartment of Internal Medicine and Clinical Oncology,University of Bari Medical School, Policlinico,Bari, ItalyTumor neovascularization forms through angiogenesis(sprouting from existing vessels) and vasculogenesis(sprouting from precursor mesenchymalcells). In embryo, cells of this type cluster and differentiateinto hematopoietic stem cells and at peripheryinto endothelial precursor cells (or angioblasts)which ultimately give rise to vessels. In post-natallife, angioblasts exist in peripheral blood and tissues,where differentiate into vessels under angiogenicstimuli, including VEGF and bFGF produced byischemie or tumor cells. Angiogenesis is importantfor progression of multiple myeloma (MM). It is alsoimportant as a prog<strong>no</strong>stic factor. Plasma cells secretegrowth and differentiation factors for endothelialcells (EC), such as VEGF, bFGF, hepatocyte growth factorand angiopoietins, which are indeed highly foundin the bone marrow than peripheral blood. Vasculogenesisin MM, however, is still under scrutiny. Herewe investigated some aspects of vasculogenesis inMM generated from bone marrow macrophages.These cells were isolated from heparinized aspirateswith anti-CD14-conjugated microbeads, and left todifferentiate into endothelial cells upon exposure toVEGF and bFGF. Macrophages were stimulated dailyfor one week with VEGF at a 50 ng/ml medium and/orbFGF at 10 ng/ml. Stimulated macrophages werestudied by immu<strong>no</strong>cytochemistry, western blot andRT-PCR for their phe<strong>no</strong>type and angiogenic capacityin the in vitro Matrigel assay. As a control, the THP-1 macrophage cell line (American Type Culture Collection)differentiated by exposure to PMA for 72hours was used. By using RT-PCR, resting macrophagesshowed expression of CD14, while <strong>no</strong>t that ofFVIII-related antigen (FVIII-RA) and CD34.By usingwestern blot and immu<strong>no</strong>localization, we showedthat stimulated macrophages developed a typicalendothelial cell phe<strong>no</strong>type, expressing FVIII-RA, VEcadherin,Tie-2/Tek and, to a lesser extent, VEGFR-2.They lost the CD68 molecule. The CD34 control moleculewas absent in the THP-1 cells as well as in bothresting and stimulated macrophages. After a 24-hourculture on matrigel and exposure to VEGF and bFGF,macrophages formed a closely-knit capillary plexuswith multicentric junctions, similar to that producedby MM endothelial cells. To sum up, these data suggestthat bone marrow macrophages of MM patientscan transform into endothelial cells under an angiogenicstimulus and contribute to MM vascularizationvia mechanisms of post-natal vasculogenesis. Resultsalso confirm that angiogenic cytokines may representa target for therapeutic management of MM.haematologica vol. <strong>89</strong>[suppl. n. 6]:september <strong>2004</strong>
VIII Congress of the Italian Society of Experimental Hematology, Pavia, September 14-16, <strong>2004</strong>107PO-073EARLY AND LATE RECOMBINATIONS AT THE IMMUNOGLOBULINκ LIGHT CHAIN LOCUS OF MUTLIPLE MYELOMA: EVIDENCE OFRAG ACTIVITY IN GERMINAL CENTERSPerfetti V,° Colli Vignarelli M,° Palladini G,°Navazza V,° Giachi<strong>no</strong> C, # Merlini G*°Department of Internal Medicine, Internal Medicineand Medical Oncology, and the *Biotech<strong>no</strong>logyResearch Laboratories, IRCCS Policlinico S. Matteo,Department of Biochemistry, University of Pavia, and#IRCCS Fondazione Maugeri, Pavia, ItalyB cells may undergo sequential rearrangements atthe light chain loci, despite already expressing lightchain receptors. This phe<strong>no</strong>me<strong>no</strong>n, k<strong>no</strong>wn as secondaryrearrangement, may occur during differentiationin the bone marrow (receptor editing) and in theperiphery, at some point of the germinal center reaction(receptor revision). To study light chain recombinationsthat preceded the development of a marrowplasma cell we used multiple myeloma as a singlecell-model and, taking advantage of the fact thatIg light chains usually rearrange before Ig ones, weused PCR to analyze the Ig locus of twenty-nine Igmyeloma cases. The results indicated that all Ig alleleswere inactivated via rearrangement of the κdeleting element, more frequently to a V segment(69%) than to the intronic recombination signalsequence (31%). Eighteen alleles (16 myelomaclones) had previous V-J attempts, and these revealedincreased utilization of distal V and J gene segments(J 56%), a marker of multiple sequential rearrangement.In-frame V-J rearrangements were found inapproximately 1/3 of available joints (5/18, with oneinvolving a V pseudogene), each one in differentmyeloma clones: 3 were identical to germline (i. e.compatible either with editing in the bone marrow orwith revision before the onset of somatic changes),while 1 had several nucleotide substitutions indicatinginactivation after the germinal center reactionhad been initiated. The present findings have relevancefor light chain genetics and support the viewthat developing B-cells may undergo both early andlate recombinations at the light chain locus. Sustainedactivity of recombination-activating genesmay contribute to immu<strong>no</strong>globulin translocations inB-cell neoplasias.PO-074CHARACTERIZATION OF ONCOGENE DYSREGULATION IN MULTI-PLE MYELOMA BY COMBINED FISH AND DNA MICROARRAYANALYSESFabris S,* Agnelli l,* Mattioli M,* Baldini l,*Ronchetti D,* Morabito F, + Verdelli D,* Nobili l,*Intini D,* Callea V, + Stelita<strong>no</strong> C, + Maiolo AT,*Lombardi L,* Neri A**Laboratorio di Ematologia Sperimentale e GeneticaMolecolare, U. O. Ematologia 1, Dipartimento diScienze Mediche, Università degli Studi di Mila<strong>no</strong>,Ospedale Maggiore IRCCS, Milan; + Divisione di Ematologiae Centro Trapianto di Midollo, Azienda Ospedaliera“Bianchi-Melacrinò-Morelli”, Reggio Calabria,ItalyMultiple myeloma (MM) is a neoplastic proliferatio<strong>no</strong>f plasma cells characterized by a marked biologicaland clinical heterogeneity. Dysregulation ofdistinct putative oncogenes, as a result of chromosomaltranslocations involving the IGH locus at14q32, occurs frequently in MM. Such oncogenicevents are thought to be linked with the transformationand clonal evolution of malignant plasmacells and may have a significance in the definition ofdifferent entities of the disease. In the present study,the expression profiles of FGFR3/MMSET, CCND1,CCND3, MAF and MAFB, involved respectively in thet(4;14)(p16.3;q32), t(11;14)(q13;q32), t(6;14)(p21;q32), t(16;14)(q23;q32), and t(14;20)(q32;q12),were investigated on purified plasma cell populationsfrom 39 MM and 6 plasma cell leukemia (PCL)patients by DNA microarray analysis and comparedwith the presence of translocations as assessed bydual-color FISH or RT-PCR. The t(4;14) was found in6 MM patients, the t(11;14) in 10 patients (9 MMand 1 PCL), the t(6;14) in one MM case, the t(14,16)in three cases (2 MM and 1 PCL), and the t(14;20) i<strong>no</strong>ne PCL. Traslocations were associated with spikedexpression of target genes in all cases. In addition,gene expression profiling allowed to the identificatio<strong>no</strong>f putative chromosomal translocations dysregulatingthe CCND1 (1 MM and 1 PCL) and MAFB (1MM and 1 PCL) without any apparent involvement ofimmu<strong>no</strong>globulin loci. Notably, all of the translocationswere found to be mutually exclusive. Interestingly,marked increased levels of MMSET expressionhave been found in one MM case in which a 4p16.3allele was localized on an unidentified chromosome.Overall, our data support the <strong>no</strong>tion that translocations(either or <strong>no</strong>t involving the IGH locus) representthe mechanism of dysregulation of putative oncogenesprimarily involved in myelomagenesis and suggestthe importance of combined molecular cytogeneticsand gene expression approaches for the detectio<strong>no</strong>f genetic aberrations in MM.haematologica vol. <strong>89</strong>[suppl. n. 6]:september <strong>2004</strong>
- Page 1 and 2:
haematologicahJournal of Hematology
- Page 3:
haematologicaeditorial boardeditor-
- Page 6:
supplement 6, September 2004Table o
- Page 9 and 10:
VIII Congress of the Italian Societ
- Page 11 and 12:
VIII Congress of the Italian Societ
- Page 13 and 14:
VIII Congress of the Italian Societ
- Page 15 and 16:
VIII Congress of the Italian Societ
- Page 18 and 19:
12Main ProgramAcknowledgments: this
- Page 20 and 21:
14Main Programhaematologica vol. 89
- Page 22 and 23:
16Oral Communicationsexpression. TR
- Page 24 and 25:
18Oral CommunicationsBEST-06NK CELL
- Page 26 and 27:
20Oral Communications: Molecular He
- Page 28 and 29:
22Oral Communications: Molecular He
- Page 30 and 31:
24Oral Communications: Hematopoieti
- Page 32 and 33:
26Oral Communications: Hematopoieti
- Page 34 and 35:
28Oral Communications: Hematopoieti
- Page 36 and 37:
30Oral Communications: Non-malignan
- Page 38 and 39:
32Oral Communicationsmodulation of
- Page 40 and 41:
34Oral Communicationsfollow-up samp
- Page 42 and 43:
36Oral Communicationsinary results
- Page 44 and 45:
38Oral Communicationslow-grade NHL)
- Page 46 and 47:
40Oral CommunicationsOral Communica
- Page 48 and 49:
42Oral Communicationsboth increased
- Page 50 and 51:
44Oral CommunicationsCO-40POTENTIAL
- Page 52 and 53:
46Oral Communicationsshowed an exte
- Page 54 and 55:
48Oral CommunicationsThe molecular
- Page 56 and 57:
50Oral Communicationsthe transcript
- Page 58 and 59:
52Oral Communicationsing to apoptot
- Page 60 and 61:
54Oral CommunicationsCO-54NEOPLASTI
- Page 62 and 63: 56Oral CommunicationsOral Communica
- Page 64 and 65: 58Oral Communicationssystem-Promega
- Page 66 and 67: 60Oral Communicationsthe relationsh
- Page 68 and 69: 62PostersPosterACUTE MYELOID LEUKEM
- Page 70 and 71: 64Postersone course of CI-FLA. Ther
- Page 72 and 73: 66Postersed to GST deletions and CY
- Page 74 and 75: 68Posterstion until optimal VPA pla
- Page 76 and 77: 70Posterseffective biotechnological
- Page 78 and 79: 72Postersdirectly to maintenance th
- Page 80 and 81: 74PostersPosterACUTE LYMPHOID LEUKE
- Page 82 and 83: 76Postersformed in half the patient
- Page 84 and 85: 78Posterspatients correlating data
- Page 86 and 87: 80Postersleukemia-related and thus
- Page 88 and 89: 82PostersCD33/CD16, CD13/CD16, CD45
- Page 90 and 91: 84PostersIn myelodysplastic syndrom
- Page 92 and 93: 86Postersin our series of 376 conse
- Page 94 and 95: 88PostersPO-041FUNCTIONAL ANALYSIS
- Page 96 and 97: 90PostersPO-044FISHING NUP98 INVOLV
- Page 98 and 99: 92Postersof AML blasts to RA. In su
- Page 100 and 101: 94Postersafter 72-96 h treatment wi
- Page 102 and 103: 96PostersPosterMOLECULAR HEMATOLOGY
- Page 104 and 105: 98Postersanalyse the transcribed HU
- Page 106 and 107: 100Postersed with the gain of the i
- Page 108 and 109: 102Postershowever, been reported in
- Page 110 and 111: 104Postersand the intrinsic apoptot
- Page 114 and 115: 108PostersPO-075NONMYELOABLATIVE AL
- Page 116 and 117: 110Posters9-12, 17-20/28 d on odd c
- Page 118 and 119: 112PostersPosterMULTIPLE MYELOMA II
- Page 120 and 121: 114Posterssion, the immunomodulator
- Page 122 and 123: 116Posters(p-ERK1/2) levels in myel
- Page 124 and 125: 118PostersPO-092ROLE OF THE MEVALON
- Page 126 and 127: 120Postershis study evaluates the p
- Page 128 and 129: 122PostersPosterNON-ONCOLOGICAL HEM
- Page 130 and 131: 124PostersPO-101A WHOLE BLOOD FLOW
- Page 132 and 133: 126Postersthat ITP DCs, after pulsi
- Page 134 and 135: 128PostersTherefore in the proposit
- Page 136 and 137: 130Postersods and early effective a
- Page 138 and 139: 132PostersPO-116FIP1L1-PDGFRA FUSIO
- Page 140 and 141: 134Postersand of course, as reducti
- Page 142 and 143: 136Posterscurrently under study bec
- Page 144 and 145: 138Postersmg/day (Haematologica 200
- Page 146 and 147: 140Postersno severe reaction were o
- Page 148 and 149: 142PostersCML for clinical and haem
- Page 150 and 151: 144PostersPO-135THE ATG-SAPORIN-S6
- Page 152 and 153: 146Postersthrough a flow cytometry-
- Page 154 and 155: 148Posterspredominant TCR peak prec
- Page 156 and 157: 150Postersrejection or cytopenia, w
- Page 158 and 159: 152Postersphocytes. Anti-leptin blo
- Page 160 and 161: 154Postersmy), which the patient re
- Page 162 and 163:
156Postersgr/m 2 +GCSF) followed by
- Page 164 and 165:
158Postersremission of 100% of MCL
- Page 166 and 167:
160Posterswould require an early an
- Page 168 and 169:
162PostersPO-165SPONTANEOUS MOBILIZ
- Page 170 and 171:
164PostersPO-168TLR7 AND TLR9 LIGAN
- Page 172 and 173:
166PostersFR and/or CDR clustering
- Page 174 and 175:
168PostersPO-174INDUCTION OF FAS UP
- Page 176 and 177:
170Postersup data were available, m
- Page 178 and 179:
172Posterssamples showing RFC methy
- Page 180 and 181:
174PostersIn the last few years the
- Page 182 and 183:
176PostersPO-187RELAPSED/REFRACTORY
- Page 184 and 185:
178Posters1.The association of prim
- Page 186 and 187:
180Posterswith generalizated lympho
- Page 188 and 189:
182PostersPO-196EPRATUZUMAB/SAPORIN
- Page 190 and 191:
184Postersantioxidant capacity of p
- Page 192 and 193:
186PostersCD16/CD56 + (NK) cells an
- Page 194 and 195:
188Postersby PBSCT, as the general
- Page 196 and 197:
190Postersnode biopsies, three from
- Page 198 and 199:
192PostersPO-212ANALYSIS OF IGV GEN
- Page 200 and 201:
194Postershaematologica vol. 89[sup
- Page 202 and 203:
IIVIII Congress of the Italian Soci
- Page 204 and 205:
IVVIII Congress of the Italian Soci
- Page 206 and 207:
VIVIII Congress of the Italian Soci
- Page 208 and 209:
VIIIVIII Congress of the Italian So
- Page 210 and 211:
XVIII Congress of the Italian Socie